| 引用本文：伍琳, 陈永法.我国创新药物研发能力的国际比较及成因分析[J].中国卫生政策研究,2017,10(8):23-28 |
|
| 我国创新药物研发能力的国际比较及成因分析 |
| 投稿时间：2017-05-19 修订日期：2017-07-31 PDF全文浏览 HTML全文浏览 |
| 伍琳, 陈永法 |
| 中国药科大学国际医药商学院 江苏南京 211198 |
| 摘要:在"创新驱动发展"以及建设医药创新强国的时代背景下，本文从资金投入、人才资源、创新产出三个方面选取指标，对我国与美、日、欧等发达医药强国的创新药物研发能力进行比较评价，以此为基础揭示我国创新能力差异产生的政策根源。实证评价结果显示，我国投入于创新药物研发的资金总量正持续增加、研发人员数量也已渐成规模，但投入强度与发达国家相比仍差距显著，资金投入结构方面缺乏合理性。这与我国财税优惠政策缺位、高端人才培养不足、产学研环境缺陷、医保政策覆盖范围较窄等原因密不可分。 |
| 关键词:创新药物 研发能力 政策成因 国际比较 |
| 基金项目:国家社会科学基金重大项目（15ZDB167）；江苏省普通高校研究生科研创新计划资助项目（KYCX17_0736）； 中国药科大学华海药业研究生创新基金资助项目（CX16S-012HH） |
|
| Novel drug research and development ability in China:An international comparison and analysis |
| WU Lin, CHEN Yong-fa |
| School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China |
| Abstract:Under the background of innovation-driven development and advanced biopharmaceutical innovative construction, this paper selects the indicators from three aspects:capital investment, talent resources and innovation output, and a comparative evaluation of the innovation drug R&D ability of China and the developed countries namely United States, Japan and Europe, as the basis to reveal the policy causes of the innovation ability discrepancies in China. The empirical results show that the total amount of funds invested in R&D of innovative drugs is increasing and the number of R&D personnel has become the scale. However, the investment intensity is still far from that of the developed countries, and the capital investment structure is also deficient of rationality. This is inseparable from the absence of preferential taxation policies, lack of high-level personnel training, environmental defects in production and research, and narrow coverage of health insurance policies. |
| Key words:Novel drug Research and development ability Policy reasons International comparison |
| 摘要点击次数: 2357 全文下载次数: 22 |
|
|
|
|
|
